CONFLICT OF INTEREST STATEMENT
Infection
INFECTION
YA provided nonpaid consultations on therapeutics for MERS for Gilead Sciences and SAB Biotherapeutics, and he is a board member of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). All other authors declare no financial or commercial conflict of interest.